Brief: GenSight Biologics Says Co Is Financed Until At Least End Of Q2 2023

Gensight Biologics SA

14/05/2021 06:41

May 14 (Reuters) - GENSIGHT BIOLOGICS SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS PROVIDES 2021 OPERATIONS UPDATE IN THE
CONTEXT OF COVID-19
    * COMPANY IS FINANCED UNTIL AT LEAST END OF Q2 2023
    * ADDITIONAL PATIENTS WERE TREATED WITH LUMEVOQ® IN FRANCE
IN Q1
2021 UNDER A NOMINATIVE TEMPORARY AUTHORIZATION FOR USE (ATU)
GRANTED BY FRENCH NATIONAL DRUG SAFETY AGENCY
    * LUMEVOQ COMMERCIAL LAUNCH IN EUROPE STILL EXPECTED IN H1
2022
    * IS ABLE TO FACE ANY EVOLUTION OF COVID-19 SITUATION WITH
AS MUCH
FLEXIBILITY AND FORESIGHT AS REQUIRED
    * COMPANY AND INVESTIGATORS TOGETHER DECIDED TO DELAY
RECRUITING
NEW PATIENTS INTO 3RD COHORT OF PIONEER PHASE I/II CLINICAL
TRIAL OF GS030 UNTIL COVID-19 SITUATION HAD IMPROVED
    * DOES NOT FORESEE ANY SHORTAGE DUE TO IMPACT OF DPA ON TFS
IN US
AND IS CLOSELY MONITORING SITUATION

Source text for Eikon:  ID:nBw3J7w5Da 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))